An international study has identified three psychological profiles associated with different patterns of cognitive and brain decline in aging. The study, which analyzed more than 1,000 middle-aged and ...

Scholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global revenue and significant growth from upcoming trials and favorable data.

Creatinine, a byproduct of muscle function, may be more sensitive in tracking SMA progression and response to treatment than ...

Patients with spinal muscular atrophy (SMA) type 2 showed improved motor ability when treated with intrathecal onasemnogene ...

Advocates rallied outside the State House on Tuesday for special education funding.The group urged lawmakers to allocate more ...

Speaking to PEOPLE exclusively, Shane and Hannah explain that their book stands as a way to celebrate partnerships like the ...

Positive results from its Phase III STEER study mean Novartis could boost sales of its OAV101 IT drug for spinal muscular ...

NORTH CHICAGO, IL and ROCKVILLE, MD, USA I January 13, 2025 I AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ...

Men with SMA are likely to have fertility issues, and patients with more severe motor impairments have lower sperm counts, ...

Crystal Rondeau’s muscle wasting disease has left her with only one finger to press an alarm button or send a text. The ...

Accessible travel blog founder Cory Lee is committed to helping other wheelchair users travel the world freely.

Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein ...